{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:34:12Z","timestamp":1790094852176,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21671-6","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:42:53Z","timestamp":1761752573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of methylprednisolone combination with abrocitinib compared to methylprednisolone combination with azathioprine in bullous pemphigoid: a retrospective study"],"prefix":"10.1038","volume":"15","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zequn","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"21671_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","volume":"94","author":"D Miyamoto","year":"2019","unstructured":"Miyamoto, D., Santi, C. G., Aoki, V. & Maruta, C. W. Bullous pemphigoid. Bras. Dermatol. 94, 133\u2013146 (2019).","journal-title":"Bras. Dermatol."},{"key":"21671_CR2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/TME.0000000000000372","volume":"43","author":"N Martinez","year":"2021","unstructured":"Martinez, N., Gadler, T., Benson, A., Lalicata, K. & Truman, L. Bullous pemphigoid: a multifactorial review of a dermatologic mystery. Adv. Emerg. Nurs. J. 43, 272\u2013278 (2021).","journal-title":"Adv. Emerg. Nurs. J."},{"key":"21671_CR3","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan, S. M. et al. Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study. Bmj-Brit Med. J. 337, a180 (2008).","journal-title":"Bmj-Brit Med. J."},{"key":"21671_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.det.2011.03.008","volume":"29","author":"H Ujiie","year":"2011","unstructured":"Ujiie, H., Nishie, W. & Shimizu, H. Pathogenesis of bullous pemphigoid. Dermatol. Clin. 29, 439\u2013446 (2011).","journal-title":"Dermatol. Clin."},{"key":"21671_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","volume":"18","author":"P Bernard","year":"2017","unstructured":"Bernard, P. & Antonicelli, F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am. J. Clin. Dermatol. 18, 513\u2013528 (2017).","journal-title":"Am. J. Clin. Dermatol."},{"key":"21671_CR6","doi-asserted-by":"publisher","first-page":"102799","DOI":"10.1016\/j.amsu.2021.102799","volume":"70","author":"SN Khalid","year":"2021","unstructured":"Khalid, S. N. et al. A blistering new era for bullous pemphigoid: A scoping review of current Therapies, ongoing clinical Trials, and future directions. Ann. Med. Surg. 70, 102799 (2021).","journal-title":"Ann. Med. Surg."},{"key":"21671_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori, L. et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European academy of dermatology and venereology (Eadv). J. Eur. Acad. Dermatol. 36, 1689\u20131704 (2022).","journal-title":"J. Eur. Acad. Dermatol."},{"key":"21671_CR8","doi-asserted-by":"publisher","first-page":"1196946","DOI":"10.3389\/fmed.2023.1196946","volume":"10","author":"WH Toh","year":"2023","unstructured":"Toh, W. H., Lee, H. E. & Chen, C. B. Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches. Front. Med-Lausanne. 10, 1196946 (2023).","journal-title":"Front. Med-Lausanne"},{"key":"21671_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","volume":"25","author":"M Karakioulaki","year":"2024","unstructured":"Karakioulaki, M., Eyerich, K. & Patsatsi, A. Advancements in bullous pemphigoid treatment: A comprehensive pipeline update. Am. J. Clin. Dermatol. 25, 195\u2013212 (2024).","journal-title":"Am. J. Clin. Dermatol."},{"key":"21671_CR10","doi-asserted-by":"publisher","first-page":"738907","DOI":"10.3389\/fimmu.2021.738907","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Efficacy and safety of dupilumab in Moderate-to-Severe bullous pemphigoid. Front. Immunol. 12, 738907 (2021).","journal-title":"Front. Immunol."},{"key":"21671_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","volume":"159","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. Evaluation of dupilumab in patients with bullous pemphigoid. Jama Dermatol. 159, 953\u2013960 (2023).","journal-title":"Jama Dermatol."},{"key":"21671_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamadermatol.2023.4508","volume":"160","author":"ST .Le","year":"2024","unstructured":".Le, S. T. et al. Rituximab and Omalizumab combination therapy for bullous pemphigoid. Jama Dermatol. 160, 107\u2013109 (2024).","journal-title":"Jama Dermatol."},{"key":"21671_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee, S., Biehl, A., Gadina, M., Hasni, S. & Schwartz, D. M. Jak-Stat signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77, 521\u2013546 (2017).","journal-title":"Drugs"},{"key":"21671_CR14","doi-asserted-by":"publisher","first-page":"6716419","DOI":"10.1155\/2017\/6716419","volume":"2017","author":"K Juczynska","year":"2017","unstructured":"Juczynska, K. et al. Expression of the Jak\/Stat Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis. Mediat Inflamm. 2017, 6716419 (2017).","journal-title":"Mediat Inflamm."},{"key":"21671_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/09546634.2016.1277179","volume":"28","author":"A Samadi","year":"2017","unstructured":"Samadi, A., Ahmad, N. S., Hashemi, A., Nassiri, K. M. & Firooz, A. Janus kinase (Jak) inhibitors for the treatment of skin and hair disorders: A review of literature. J. Dermatol. Treat. 28, 476\u2013483 (2017).","journal-title":"J. Dermatol. Treat."},{"key":"21671_CR16","first-page":"4","volume":"27","author":"M Shalabi","year":"2022","unstructured":"Shalabi, M. et al. Janus kinase and tyrosine kinase inhibitors in dermatology: A review of their Utilization, safety profile and future applications. Skin. Therapy Lett. 27, 4\u20139 (2022).","journal-title":"Skin. Therapy Lett."},{"key":"21671_CR17","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang, I. H., Chung, W. H., Wu, P. C. & Chen, C. B. Jak-Stat signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front. Immunol. 13, 1068260 (2022).","journal-title":"Front. Immunol."},{"key":"21671_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","volume":"98","author":"HA Miot","year":"2023","unstructured":"Miot, H. A. et al. Jak-Stat pathway inhibitors in dermatology. Bras. Dermatol. 98, 656\u2013677 (2023).","journal-title":"Bras. Dermatol."},{"key":"21671_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","volume":"152","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky, E. et al. The role of Janus kinase signaling in the pathology of atopic dermatitis. J. Allergy Clin. Immun. 152, 1394\u20131404 (2023).","journal-title":"J. Allergy Clin. Immun."},{"key":"21671_CR20","doi-asserted-by":"publisher","first-page":"1220887","DOI":"10.3389\/fimmu.2023.1220887","volume":"14","author":"D Huang","year":"2023","unstructured":"Huang, D., Zhang, Y., Kong, L., Lu, J. & Shi, Y. Janus kinase inhibitors in autoimmune bullous diseases. Front. Immunol. 14, 1220887 (2023).","journal-title":"Front. Immunol."},{"key":"21671_CR21","doi-asserted-by":"publisher","first-page":"e15754","DOI":"10.1111\/dth.15754","volume":"35","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y., Xiang, H. & Li, W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor baricitinib. Dermatol. Ther. 35, e15754 (2022).","journal-title":"Dermatol. Ther."},{"key":"21671_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2022.10.028","volume":"32","author":"S Youssef","year":"2023","unstructured":"Youssef, S., Gallitano, S. & Bordone, L. A. Two cases of bullous pemphigoid effectively treated with oral Tofacitinib. JAAD Case Rep. 32, 77\u201380 (2023).","journal-title":"JAAD Case Rep."},{"key":"21671_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdcr.2022.12.006","volume":"32","author":"D Nash","year":"2023","unstructured":"Nash, D. & Kirchhof, M. G. Bullous pemphigoid treated with Janus kinase inhibitor Upadacitinib. JAAD Case Rep. 32, 81\u201383 (2023).","journal-title":"JAAD Case Rep."},{"key":"21671_CR24","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1111\/jdv.19475","volume":"38","author":"W Jiang","year":"2024","unstructured":"Jiang, W., Ma, X., Guo, T., Song, M. & Zhang, J. Abrocitinib-a promising option for patients with refractory bullous pemphigoid. J. Eur. Acad. Dermatol. 38, e119\u2013e121 (2024).","journal-title":"J. Eur. Acad. Dermatol."},{"key":"21671_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"DF Murrell","year":"2012","unstructured":"Murrell, D. F. et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J. Am. Acad. Dermatol. 66, 479\u2013485 (2012).","journal-title":"J. Am. Acad. Dermatol."},{"key":"21671_CR26","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","volume":"145","author":"S Egami","year":"2020","unstructured":"Egami, S., Yamagami, J. & Amagai, M. Autoimmune bullous skin Diseases, pemphigus and pemphigoid. J. Allergy Clin. Immun. 145, 1031\u20131047 (2020).","journal-title":"J. Allergy Clin. Immun."},{"key":"21671_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","volume":"11","author":"CM Hammers","year":"2016","unstructured":"Hammers, C. M. & Stanley, J. R. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu. Rev. Pathol-Mech. 11, 175\u2013197 (2016).","journal-title":"Annu. Rev. Pathol-Mech"},{"key":"21671_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1684\/ejd.2018.3366","volume":"28","author":"E Cozzani","year":"2018","unstructured":"Cozzani, E., Gasparini, G., Di Zenzo, G. & Parodi, A. Immunoglobulin E and bullous pemphigoid. Eur. J. Dermatol. 28, 440\u2013448 (2018).","journal-title":"Eur. J. Dermatol."},{"key":"21671_CR29","doi-asserted-by":"publisher","first-page":"1220887","DOI":"10.3389\/fimmu.2023.1220887","volume":"14","author":"D. Huang","year":"2023","unstructured":"Huang, D. et al.Janus Kinase Inhibitors in Autoimmune Bullous DiseasesFront Immunol. 14,1220887 (2023).","journal-title":"Front Immunol."},{"key":"21671_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/bjd\/ljac078","volume":"188","author":"B Fan","year":"2023","unstructured":"Fan, B. & Wang, M. Tofacitinib in recalcitrant bullous pemphigoid: A report of seven cases. Brit J. Dermatol. 188, 432\u2013434 (2023).","journal-title":"Brit J. Dermatol."},{"key":"21671_CR31","doi-asserted-by":"crossref","unstructured":"Iznardo, H., Ro\u00e9, E., Serra-Baldrich, E. & Puig, L. Efficacy and safety of Jak1 inhibitor abrocitinib in atopic dermatitis. Pharmaceutics 15, (2023).","DOI":"10.3390\/pharmaceutics15020385"},{"key":"21671_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","volume":"83","author":"R Abdat","year":"2020","unstructured":"Abdat, R. et al. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. J. Am. Acad. Dermatol. 83, 46\u201352 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"21671_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly, P. et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. New. Engl. J. Med. 346, 321\u2013327 (2002).","journal-title":"New. Engl. J. Med."},{"key":"21671_CR34","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/jid.2008.412","volume":"129","author":"P Joly","year":"2009","unstructured":"Joly, P. et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: A multicenter randomized study. J. Invest. Dermatol. 129, 1681\u20131687 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"21671_CR35","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/1346-8138.16412","volume":"49","author":"CL Chen","year":"2022","unstructured":"Chen, C. L. et al. Association between bullous pemphigoid and risk of venous thromboembolism: A nationwide population-based cohort study. J. DERMATOL. 49, 753 (2022).","journal-title":"J. DERMATOL."},{"key":"21671_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaad.2024.02.052","volume":"91","author":"K Bonnesen","year":"2024","unstructured":"Bonnesen, K., Poulsen, C., Schmidt, S., S\u00f8rensen, H. T. & Schmidt, M. Autoimmune blistering disorders and cardiovascular risks: A population-based cohort study. J. Am. Acad. Dermatol. 91, 82 (2024).","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21671-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21671-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21671-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:42:55Z","timestamp":1761752575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21671-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21671"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21671-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37902"}}